共 125 条
- [1] Muskiet MH(2015)Pleiotropic effects of type 2 diabetes management strategies on renal risk factors Lancet Diabetes Endocrinol 3 367-381
- [2] Tonneijck L(2016)Gastrointestinal actions of GLP-1 based therapies: glycaemic control beyond the pancreas Diabetes Obes Metab 18 224-235
- [3] Smits MM(2014)The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 10 88-103
- [4] Smits MM(2012)Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis Diabetes Obes Metab 14 596-600
- [5] Tonneijck L(2015)Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med 373 2247-2257
- [6] Muskiet MH(2004)Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J Clin Endocrinol Metab 89 3055-3061
- [7] Muskiet MH(2013)Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat Am J Physiol Renal Physiol 304 F137-F144
- [8] Smits MM(2013)Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men J Clin Endocrinol Metab 98 664-671
- [9] Morsink LM(2015)Renal Extraction and Acute Effects of Glucagon-like peptide-1 on Central and Renal Hemodynamics in Healthy Men Am J Physiol Endocrinol 15 E641-E649
- [10] Diamant M(2016)Acute renal haemodynamic effects of GLP-1 receptor agonist exenatide in healthy overweight males Diabetes Obes Metab 18 178-185